Novartis announced that the U.S. Food and Drug Administration granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises in patients of all genotypes with sickle cell disease.
The U.S. Food and Drug Administration approved Eli Lilly and Co.’s migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
Cancer treatments from Pfizer Inc. and Exelixis Inc. won expanded approval from the U.S. FDA for use in previously untreated patients.
Three times is not the charm. New York-based Ophthotech Corporation announced that its Fovista (pegpleranib) failed yet another Phase III clinical trial.
Drugmaker Eli Lilly and Co. said its acute migraine drug lasmiditan succeeded in a key late-stage study, setting the stage for U.S. regulatory approval.
Proteon Therapeutics Inc. said its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study.
Adults with longer-lived parents have a lower-than-average risk for problems with the body’s circulatory system in middle age, British researchers have found.
(Reuters Health) – Eating a handful of walnuts each day might help keep the doctor away, at least for some people who are at risk of developing diabetes, a U.S. study suggests. When people in the study added 56 grams of walnuts (2 ounces, or about 14 walnuts) to their daily diet for six months, […]